Αποτελέσματα Αναζήτησης
25 Φεβ 2015 · New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Unlike VKAs, these anticoagulants do not require routine INR monitoring and possess favorable pharmacological properties.
12 Οκτ 2020 · With the goal of developing a new class of anticoagulants associated with a lower risk of bleeding than currently available agents, dozens of drugs targeting the contact system are now in development.
New oral anticoagulants include direct inhibitors of thrombin, factor Xa and factor IXa. Designed to provide more streamlined anticoagulation than warfarin, these agents can be given without routine coagulation monitoring.
28 Αυγ 2022 · Asundexian is a new oral anticoagulant that inhibits factor XIa. By working upstream in the contact activation pathway of coagulation, factor XIa inhibitors may prevent pathologic thrombosis, and thus recurrent ischaemic events, but not adversely impact haemostasis, and thus not cause bleeding. 7
17 Ιουν 2022 · Asundexian showed factor XI inhibition upwards of 90% with daily dosing in PACIFIC-AF. Factor XIa inhibition represents a promising strategy to reduce stroke risk while preserving a patient's ability to clot when bleeding.
19 Μαρ 2015 · The non-vitamin K antagonist oral anticoagulants are already replacing low-molecular-weight heparin for thromboprophylaxis in patients undergoing elective hip or knee arthroplasty and replacing warfarin for stroke prevention in patients with atrial fibrillation and treatment of venous thromboembolism.
18 Οκτ 2024 · Anticoagulant therapy has long been crucial in managing atrial fibrillation, a common heart rhythm disorder associated with a significant risk of stroke, cognitive decline, systemic embolism, and an increase in disability-adjusted life years (for further reading, see appendix p 6).
